MA46523A - Procédés de criblage de modulateurs d'une activité biologique de type gdf15 - Google Patents

Procédés de criblage de modulateurs d'une activité biologique de type gdf15

Info

Publication number
MA46523A
MA46523A MA046523A MA46523A MA46523A MA 46523 A MA46523 A MA 46523A MA 046523 A MA046523 A MA 046523A MA 46523 A MA46523 A MA 46523A MA 46523 A MA46523 A MA 46523A
Authority
MA
Morocco
Prior art keywords
gdf15
processes
biological activity
type biological
screening modulators
Prior art date
Application number
MA046523A
Other languages
English (en)
Inventor
Anthony Armstrong
Stephen Beck
Jose Antonio Chavez
Chen-Ni Chin
Thai Dinh
Jennifer Furman
Matt Husovsky
Xiefan Lin-Schmidt
Shannon Mullican
Shamina Rangwala
Vicki South
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of MA46523A publication Critical patent/MA46523A/fr

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/0004Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/136Screening for pharmacological compounds
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475Assays involving growth factors
    • G01N2333/495Transforming growth factor [TGF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Obesity (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
MA046523A 2016-10-12 2017-10-11 Procédés de criblage de modulateurs d'une activité biologique de type gdf15 MA46523A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662407046P 2016-10-12 2016-10-12

Publications (1)

Publication Number Publication Date
MA46523A true MA46523A (fr) 2019-08-21

Family

ID=60186389

Family Applications (1)

Application Number Title Priority Date Filing Date
MA046523A MA46523A (fr) 2016-10-12 2017-10-11 Procédés de criblage de modulateurs d'une activité biologique de type gdf15

Country Status (9)

Country Link
US (1) US20190234935A1 (fr)
EP (1) EP3526346A1 (fr)
JP (1) JP2020503842A (fr)
KR (1) KR20190059312A (fr)
AU (1) AU2017342028A1 (fr)
CA (1) CA3038846A1 (fr)
IL (1) IL265808A (fr)
MA (1) MA46523A (fr)
WO (1) WO2018071493A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY194669A (en) 2016-03-31 2022-12-12 Ngm Biopharmaceuticals Inc Binding Proteins and Methods of use Thereof
US10336812B2 (en) * 2016-05-10 2019-07-02 Janssen Biotech, Inc. GDF15 fusion proteins and uses thereof
EP3833974A2 (fr) 2018-08-10 2021-06-16 Novartis AG Domaines extracellulaires gfral et procédés d'utilisation
EA202191105A1 (ru) 2018-10-22 2021-08-03 Янссен Фармацевтика Нв Слитые белки, полученные из глюкагоноподобного пептида 1 (glp1) и ростового фактора дифференцировки 15 (gdf15), и их применение
KR20220150270A (ko) 2019-10-07 2022-11-10 칼리오페, 인크. Gpr119 효능제
TW202140440A (zh) 2020-02-28 2021-11-01 美商克力歐普股份有限公司 Gpr40激動劑
WO2021236617A1 (fr) 2020-05-19 2021-11-25 Kallyope, Inc. Activateurs d'ampk
CN116390925A (zh) 2020-06-26 2023-07-04 卡尔优普公司 Ampk活化剂
WO2023154953A1 (fr) 2022-02-14 2023-08-17 Ngm Biopharmaceuticals, Inc. Polypeptides gdf15 pour le traitement et la prévention de maladies auto-immunes
JP2026505740A (ja) * 2023-01-20 2026-02-18 コリア アドバンスト インスティチュート オブ サイエンス アンド テクノロジー Gfralを標的にするアンチセンスオリゴマー及びこの用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5723286A (en) 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
US5770358A (en) 1991-09-18 1998-06-23 Affymax Technologies N.V. Tagged synthetic oligomer libraries
KR100310939B1 (ko) 1992-10-01 2002-06-20 추후제출 태그로암호화한복합조합화학라이브러리
BR9407947A (pt) 1993-11-02 1996-11-26 Affymax Tech Nv Processo para sintetizar moléculas diversas em uma pluralidade de substratos e uma coleçao molecular etiquetade para realizaçao reaçoes de copulaçao em contas em paralelo para triar uma coleçao molecular etiquetada para detectar a presença de um ou mais diferentes etiquetas e para determinar a sequência de síntese aparelho para reaçoes de copulaçao paralelas em suportes sólidos bloco de alinhamento ótico para uso com um detector ótico sistemas de distribuiçao para distribuir reagentes dispositiv
CA2189634A1 (fr) 1994-05-06 1995-11-16 John J. Baldwin Bibliotheque combinatoire de dihydrobenzopyranes
US5663046A (en) 1994-06-22 1997-09-02 Pharmacopeia, Inc. Synthesis of combinatorial libraries
US6010861A (en) 1994-08-03 2000-01-04 Dgi Biotechnologies, Llc Target specific screens and their use for discovering small organic molecular pharmacophores
EP2441466B1 (fr) * 2004-04-13 2014-07-23 St Vincent's Hospital Sydney Limited Agent inhibiteur de MIC-1
EP2694092B1 (fr) * 2011-04-08 2017-01-04 Amgen Inc. Méthode de traitement ou d'amélioration de troubles métaboliques à l'aide du facteur 15 de différenciation de croissance (gdf-15)
EP3683228A3 (fr) * 2012-01-26 2020-07-29 Amgen Inc. Polypeptides du facteur de croissance et de différenciation 15 (gdf-15)
RS59700B1 (sr) * 2014-03-26 2020-01-31 Univ Wuerzburg J Maximilians Monoklonalna antitela za faktor 15 (gdf-15) rasta i diferencijacije, i njihove upotrebe u lečenju kancerske kaheksije i kancera
JP6910800B2 (ja) * 2014-06-20 2021-07-28 アベオ ファーマシューティカルズ, インコーポレイテッド Gdf15調節剤を用いたうっ血性心不全及びその他の心機能不全の治療
PL3197493T3 (pl) * 2014-09-25 2021-08-23 Aveo Pharmaceuticals Inc. Sposoby odwracania kacheksji i przedłużania przeżycia obejmujące podanie modulatora gdf15 i środka przeciwnowotworowego
CN108697795A (zh) * 2016-02-29 2018-10-23 伊莱利利公司 Gfral受体疗法
MY194669A (en) * 2016-03-31 2022-12-12 Ngm Biopharmaceuticals Inc Binding Proteins and Methods of use Thereof

Also Published As

Publication number Publication date
US20190234935A1 (en) 2019-08-01
WO2018071493A1 (fr) 2018-04-19
IL265808A (en) 2019-06-30
KR20190059312A (ko) 2019-05-30
CA3038846A1 (fr) 2018-04-19
EP3526346A1 (fr) 2019-08-21
AU2017342028A1 (en) 2019-04-11
JP2020503842A (ja) 2020-02-06

Similar Documents

Publication Publication Date Title
MA46523A (fr) Procédés de criblage de modulateurs d'une activité biologique de type gdf15
FR24C1022I1 (fr) Modulation d'activité du complément
MA56008A (fr) Composés et compositions pour traiter des états associés à une activité de nlrp
MA46278A (fr) Molécules de liaison qui modulent une activité biologique exprimée par une cellule
MA50636A (fr) Compositions et procédés pour inhiber l'activité d'arginase
EP3383168A4 (fr) Procédés de modification génétique de plantes
EP3250230A4 (fr) Modulateurs d'activité du complément
EP3409108A4 (fr) Couvre-lit pour lit d'animaux de compagnie
EP3313385A4 (fr) Agents d'alkylation d'adn contenant de l'aziridine
EP3356832A4 (fr) Biomarqueurs et procédés d'évaluation de l'activité de la maladie arthrite psoriasique
EP3852617A4 (fr) Procédés de réversion d'activité de ticagrélor
EP3398776A4 (fr) Composant de buse d'imprimante biologique et imprimante biologique
EP3638283C0 (fr) Antagonistes de canaux calciques de type cav2.3 r pour le traitement de maladies neurodégénératives
EP3356523A4 (fr) Machines d'état biologique
EP3898438A4 (fr) Bouteille à auto-agitation
EP3261631A4 (fr) Inhibition de l'activité d'olig2
EP3471534A4 (fr) Végétaux à activité de la lipase 1 réduite
IL282700A (en) Heterocyclic compounds for the treatment of epilepsy
MA41198A (fr) Essais d'activité enzymatique pour i2s
EP3480598A4 (fr) Procédé de criblage d'anticorps à l'aide de cellules dérivées de patients
EP3356515A4 (fr) Test d'activité biologique cellulaire
EP3603610A4 (fr) Inhibiteur de l'activité de trpa1
EP3597040A4 (fr) Agent de lutte contre les maladies des plantes
EP3506748A4 (fr) Procédés améliorés pour la synthèse de perméthrine
EP3504195A4 (fr) Inhibition de l'activité d'olig2